Informasjon

Hva er årsakene til beinskjørhet?

Vil du vite mer?

Beinskjørhet - en oversikt
Hva øker risikoen for å få beinskjørhet?
Hvordan påvises beinskjørhet?
Beintetthetsmålinger
Hvordan behandles beinskjørhet med medikamenter?
Hva kan du gjøre selv?
Fall og fallskader hos eldre
Forebygging av fall
Bisfosfonater
Hypertyreose
Hyperparatyreoidisme
Cushings sykdom
Cøliaki
Crohns sykdom
Ulcerøs kolitt
Leddgikt
Bekhterevs sykdom
Kortikosteroid
Antiepileptika
Osteoporose - for helsepersonell

Vil du vite mer?

Få tilgang på artikkelen om dette temaet fra Legehandboka.no

Artikkelen inneholder all informasjon norske allmennleger bruker i sitt daglige arbeid.

Jeg har lest og akseptert Brukervilkår ved kjøp av NEL-dokumenter

Dette dokumentet er basert på det profesjonelle dokumentet "Osteoporose". Referanselisten for dette dokumentet vises nedenfor.

Qaseem A, Forciea MA, McLean RM, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017. pmid:28492856 PubMed
Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med 2016; 374:254-262. www.nejm.org
World Health Organization (WHO). WHO scientific group on the assessment of osteoporosis at primary health care level: summary meeting report. Siden besøkt 30.09.2019. www.who.int
Berntsen GKR. Interpretation of forearm bone mineral density: the Tromsø study. Dr.gradsavhandling, Univ. i Tromsø. ISM skriftserie, nr 56, 2000.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-95. Journal of the American Medical Association
Syversen U, Halse JI. Medikamentell behandling av osteoporose. Tidsskr Nor Lægeforen 2003; 123: 2263-4. PubMed
Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int. 2000;11(8):669-74. PMID: 11095169 PubMed
Lowe KE, Mansfield KE, Delmestri A, et al. Atopic eczema and fracture risk in adults: A population-based cohort study. J Allergy Clin Immunol 2019. doi:10.1016/j.jaci.2019.09.015 DOI
Starup-Linde J, Rosendahl SB, Storgaard M, Langdahl B. Management of osteoporosis in patients living with HIV - a systematic review and meta-analysis. J Acquir. Immune Defic Syndr 2020; 83: 1-8. pmid:31809356 PubMed
Vestergaard P, Laursen LC, Schwarz P, Brixen K. Glukokortikoidinduceret osteoporose. Ugeskr Læger 2005; 167: 898-900. PubMed
Joakimsen RM, Fønnebø V. Bør det innføres screening for osteoporose i Norge? Tidsskr Nor Lægeforen 2001; 121: 615-8. Tidsskrift for Den norske legeforening
Norsk Endokrinologisk Forening. Osteoporose. I Nasjonal veileder i endokrinologi. Publisert 05.03.2019. Siden lest 18.11.2019. www.prosedyrer.no
Nasjonal faglig retningslinje for bildediagnostikk ved ikke-traumatiske muskel- og skjelettlidelser. Anbefalinger for primærhelsetjenesten. Oslo, Helsedirektoratet 2014 www.helsebiblioteket.no
Cummings SR, Lui L-Y, Eastell R, Allen IE. Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates A Meta-analysis. JAMA Intern Med 2019. pmid:31424486 PubMed
Hinton PS, Nigh P, Thyfault J. Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: a 12-month randomized, clinical trial. Bone 2015;79:203-212. PMID: 19421702 PubMed
Sherrington C, Whitney JC, Lord SR, et al. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc. 2008 Dec;56(12):2234-43. PMID: 19093923. PubMed
Santesso N, Carrasco-Labra A, Brignardello-Petersen R. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2014; 3: CD001255. doi:10.1002/14651858.CD001255.pub5 DOI
Koike T, Orito Y, Toyoda H, et al. External hip protectors are effective for the elderly with higher-than-average risk factors for hip fractures. Osteoporosis Int 2009; 20: 1613.20. pmid:19137351 PubMed
Yao P, Bennett D, Mafham M, et al. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. JAMA Netw Open 2019; 2: e1917789. pmid:31860103 PubMed
Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014 Apr 14;4:CD000227. Cochrane (DOI)
Reid I, Bolland M, et.al. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2013. doi:10.1016/S0140-6736(13)61647-5. DOI
Bolland MJ, Leung W, Tai V, et al. Calcium intake and risk of fracture: systematic review. BMJ. 2015 Sep 29;351:h4580. doi: 10.1136/bmj.h4580 DOI
Warensjö E, Byberg L, Melhus H, et al. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 2011; 342: d1473. BMJ (DOI)
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, Coyle D, Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD001155. DOI: 10.1002/14651858.CD001155.pub2. DOI
Eriksen EF, Halse J. Når seponere bisfosfonater?. Tidsskr Nor Legeforen 2012; 132: 1630-2. Tidsskrift for Den norske legeforening
Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783-9. Journal of the American Medical Association
Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofacial Surg Clin N Am 2007; 19: 487-98. PubMed
Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft . N Engl J Med 2011; 364: 1728-37. DOI: 10.1056/NEJMoa1010650 DOI
Serrano AJ, Begona L, Anitua E, Cobos R, Orive G. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol. 2013 Dec;29(12):1005-14. PMID: 24063695 PubMed
Reid DM, Devogelaer J-P, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-63. PMID: 19362675 PubMed
Faggruppe for osteoporose og benhelse, Norsk ortopedisk forening. Behandlingsveileder for menn og kvinner ≥ 50 år, med lavenergibrudd. Publisert 2015. legeforeningen.no
Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006 Jun;17(6):897-907. PMID: 16547070 PubMed
Brown JP, Roux C, Ho PR, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.. Osteoporos Int. 2014 Mar 28. pmid:24676847 PubMed
Diédhiou D, Cuny T, Sarr A, et al. Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review. Ann Endocrinol (Paris). 2015 Dec;76(6):650-7. Epub 2015 Nov 27. pmid: 26639186 PubMed
Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019; 104: 1595-622. pmid:30907953 PubMed
Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013. doi:doi:10.1016/S0140-6736(13)60856-9 DOI
Kendler DL, Marin F, Zerbini CAF, et al.: Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018; 391: 230-40. pmid:29129436 PubMed
Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60: 3346-55. pmid:19877063 PubMed
Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007 Aug;18(8):1023-31. PMID: 17308956 PubMed
Newman M, Minns Lowe C, Barker K. Spinal Orthoses for Vertebral Osteoporosis and Osteoporotic Vertebral Fracture: A Systematic Review. Arch Phys Med Rehabil 2015. pmid:26615791 PubMed
Hagen G, Wisløff T, Falch J, et al. Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway. Rapport fra kunnskapssenteret nr 10 - 2011.
Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016 Oct 5;10:CD001347. pmid: 27706804 PubMed
Zhao J-G, Zeng X-T, Wang J, et al. Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults A Systematic Review and Meta-analysis. JAMA 2017; 318: 2466-82. pmid:29279934 PubMed
Burt LA, Billington EO, Rose MS, et al. Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial. JAMA. 2019 Aug 27;322(8):736-745. PMID: 31454046 PubMed
Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365: 1621-8. PubMed
Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of supplementation with calcium and cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330: 1003-6. British Medical Journal
Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012; 366: 225-33. New England Journal of Medicine
Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522-32. pmid:14555255 PubMed
Chen P, Krege JH, Adachi JD, et al. Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res 2009; 24: 495-502. pmid:19016585 PubMed
Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011; 22: 983-91. pmid:21052642 PubMed
Muncie HL Jr, LeBlanc LL. Monitoring osteoporosis treatment: DXA should not be routinely repeated. Am Fam Physician. 2010 Oct 1;82(7):749-54. PMID: 20879697 PubMed
Maraka S, Kennel KA.. Bisphosphonates for the prevention and treatment of osteoporosis.. BMJ 2015; 351: h3783. pmid:26333528 PubMed
Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006; 21: 292-9. pmid:16418785 PubMed
Delmas PD, Munoz F, Black DM, et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 2009; 24: 1544-51. pmid:19338427 PubMed
Eastell R, Krege JH, Chen P, et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006; 22: 61-6. pmid:16393431 PubMed
McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014. doi:10.1056/NEJMoa1305224 DOI
Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367: 2010-8. PubMed
Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the national bone health alliance working group. Osteoporosis Int 2014; 25: 1439-43. pmid:24577348 PubMed

Meld deg på nyhetsbrev

Er du helsepersonell?

Ved å oppgi dette kan du få bedre tilpasset innhold om du har formell helsefaglig kompetanse

Annonsørinnhold

Annonsørinnhold fra Helsedirektoratet

Koronavirus – beslutninger og anbefalinger: Behandling

Denne samleartikkelen er en veileder Helsedirektoratet har utviklet for å kunne bidra som beslutningsstøtte rundt problemstillinger som omhandler behandling, utstyr og legemidler angående covid-19.

T-01

Mest lest i dag

Livsstil

Symptomer på infeksjon med coronavirus

Symptomene på infeksjon med coronaviruset, COVID-19, er ved sykdommens start nokså like symptomene ved forkjølelse og mild influensa. De mest alvorlige symptomene kommer oftest en stund ut i forløpet av sykdommen.

Infeksjoner

Covid-19, forkjølelse eller allergi?

Symptomene på covid-19, forkjølelse, influensa og allergi kan være nokså like. I denne artikkelen kan du lese om hvilke symptomer som er mest dominerende ved de ulike tilstandene.

Barn

Asperger syndrom

Asperger syndrom gir seg vanligvis tilkjenne fra rundt treårsalderen ved problemer med samspill med andre mennesker og begrenset, repeterende atferd og interesser.

Hva er årsakene til beinskjørhet?

Hopp til innhold

Vil du vite mer?

Er du helsepersonell?

Andre leste også dette

Beinskjørhet, hva kan du gjøre selv?

Hva øker risikoen for å få beinskjørhet?

Hva er årsakene til cøliaki?

Annonsørinnhold

Koronavirus – beslutninger og anbefalinger: Behandling

Mest lest i dag

Symptomer på infeksjon med coronavirus

Covid-19, forkjølelse eller allergi?

Asperger syndrom